ganirelix gedeon richter
chemical works of gedeon richter plc. (gedeon richter plc.) - ganirelix acetate - reproductive techniques, assisted; ovulation induction; infertility, female - hypofysiske og hypotalamiske hormoner og analoger - prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).
ganirelix "orifarm" 0,25 mg/0,5 ml injektionsvæske, opløsning i fyldt injektionssprøjte
orifarm generics a/s - ganirelixacetat - injektionsvæske, opløsning i fyldt injektionssprøjte - 0,25 mg/0,5 ml
ganirelix "paranova" 0,25 mg/0,5 ml injektionsv?ske, opl?sning i fyldt injektionsspr?jte
paranova danmark a/s - ganirelixacetat - injektionsvæske, opløsning i fyldt injektionssprøjte - 0,25 mg/0,5 ml
orgalutran
n.v. organon - ganirelix - reproductive techniques, assisted; ovulation induction; infertility, female - hypofysiske og hypotalamiske hormoner og analoger - forebyggelse af for tidlig luteiniserende hormonforstyrrelser hos kvinder, der gennemgår kontrolleret ovariehyperstimulering for assisterede reproduktionsteknikker. i kliniske undersøgelser, orgalutran blev brugt med rekombinant human follikel-stimulerende hormon eller corifollitropin alfa, vedvarende follikel stimulerende.
fyremadel 0,25 mg/0,5 ml injektionsvæske, opløsning i fyldt injektionssprøjte
sun pharmaceutical industries europe bv - ganirelixacetat - injektionsvæske, opløsning i fyldt injektionssprøjte - 0,25 mg/0,5 ml
fyremadel 0,25 mg/0,5 ml injektionsvæske, opløsning i fyldt injektionssprøjte
2care4 aps - ganirelix - injektionsvæske, opløsning i fyldt injektionssprøjte - 0,25 mg/0,5 ml
fyremadel 0,25 mg/0,5 ml injektionsv?ske, opl?sning i fyldt injektionsspr?jte
orifarm a/s - ganirelixacetat - injektionsvæske, opløsning i fyldt injektionssprøjte - 0,25 mg/0,5 ml
cosentyx
novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunosuppressiva - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriasis arthritiscosentyx, alene eller i kombination med methotrexat (mtx), er indiceret til behandling af aktiv psoriasis artrit hos voksne patienter, når svar på tidligere sygdomsmodificerende anti-reumatiske lægemidler (dmard) behandling har været mangelfuld. aksial spondyloarthritis (axspa)ankyloserende spondylitis (som, røntgen aksial spondyloarthritis)cosentyx er indiceret til behandling af aktiv ankyloserende spondylitis i voksne, der har reageret tilstrækkeligt til konventionel behandling. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
vidaza
bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
azacitidine mylan
mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.